The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis
Abstract
BACKGROUND AND OBJECTIVES: The recent significant increase in the number of immigrants entering the European Union from South and Central America means that chronic Chagas' disease is an increasingly frequent diagnosis among immigrants in Europe. Our objectives were to evaluate published evidence on the treatment of chronic Chagas' disease with benznidazole and on the potential benefits of this drug in the chronic phase of the disease. METHODS: We performed a systematic review and meta-analysis by means of an electronic search of the published literature, with no language restrictions, until October 2008. We included studies on chronically infected patients of any age who were in the indeterminate phase or had visceral involvement and for whom treatment with benznidazole was compared with placebo or no treatment. The primary endpoint was response to therapy (whether serological, parasitological or clinical), as it was measured in each of the studies included. Clinical response to therapy was also analysed. RESULTS: We identified 696 studies, from which we chose 9: 3 clinical trials and 6 observational studies. Compared with placebo or no treatment, benznidazole increases 18-fold the probability of a response to therapy [global odds ratio (OR), 18.8; 95% confidence interval (CI), 5.2-68.3]. This effect was mainly observed in clinical trials (OR, 70.8; 95% CI, 16-314), whereas in observational studies it was much less marked (OR, 7.8; 95% CI, 2.1-28.9), and even less so when only observational studies in adults were considered (OR, 6.3; 95% CI, 1.6-24.7). Patients treated with benznidazole had a significantly lower risk of clinical events (OR, 0.29; 95% CI, 0.16-0.53). Up to 18% of patients discontinued treatment due to toxicity (cutaneous reactions followed by gastrointestinal disturbances); this was less common in children than in adults. CONCLUSIONS: Analysis of available information reveals that the efficacy of treatment in late chronic infection is doubtful. Although data generally point to a beneficial effect, this could be marginal. This uncertainty is largely the result of differences in the study populations, endpoints and follow-up periods, and the fact that almost all of the information on treatment in the late chronic phase comes from non-randomized studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis Spurious precision? Meta-analysis of observational studies
Egger, M., Schneider, M., & Smith, G. D. (1998) · BMJ · doi:10.1136/bmj.316.7125.140 · Cited by 997
Cited by
Pérez-Molina, J. A., & Molina, I. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31612-4 · Cited by 1,284
Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy
Morillo, C. A., Marin-Neto, J. A., Avezum, A., Sosa-Estani, S., Rassi, A., Rosas, F., Villena, E., Quiroz, R., Bonilla, R., Britto, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507574 · Cited by 1,014
Bern, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1410150 · Cited by 770
Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease
Molina, I., Gómez i Prat, J., Salvador, F., Treviño, B., Sulleiro, E., Serre, N., Pou, D., Roure, S., Cabezos, J., Valerio, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313122 · Cited by 604
2025 ESC Guidelines for the management of myocarditis and pericarditis
Schulz-Menger, J., Collini, V., Gröschel, J., Adler, Y., Brucato, A., Christian, V., Ferreira, V. M., Gandjbakhch, E., Heidecker, B., Kerneis, M., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf192 · Cited by 434
Metadata
- Authors
- Perez-Molina, J. A., Perez-Ayala, A., Moreno, S., Fernandez-Gonzalez, M. C., Zamora, J., & Lopez-Velez, R.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-10-09
- Volume
- 64
- Issue
- 6
- Pages
- 1139-1147
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2162778646
- Cited by
- 199
- References
- 1
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.